Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 20.8% in December

Generation Bio Co. (NASDAQ:GBIO) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 37,732 shares, a decrease of 20.8% from the December 15th total of 47,657 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 76,246 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 76,246 shares, the short-interest ratio is presently 0.5 days. Currently, 0.7% of the company’s shares are sold short.

Institutional Trading of Generation Bio

Hedge funds have recently made changes to their positions in the company. Militia Capital Partners LP purchased a new stake in shares of Generation Bio during the second quarter worth $174,000. Acadian Asset Management LLC raised its position in shares of Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock worth $468,000 after buying an additional 407,843 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Generation Bio during the second quarter valued at $47,000. Marshall Wace LLP bought a new position in Generation Bio in the 2nd quarter worth about $37,000. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Generation Bio during the 3rd quarter valued at about $606,000. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Stock Performance

NASDAQ:GBIO traded down $0.02 during trading on Monday, reaching $5.62. The company’s stock had a trading volume of 98,807 shares, compared to its average volume of 54,734. Generation Bio has a 12 month low of $3.00 and a 12 month high of $10.40. The firm has a market cap of $37.88 million, a price-to-earnings ratio of -0.60 and a beta of 2.05. The firm has a 50 day moving average of $5.43 and a 200-day moving average of $5.45.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($3.18) by $2.36. The company had revenue of $1.59 million during the quarter, compared to analyst estimates of $0.66 million. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. Equities research analysts forecast that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GBIO shares. Citigroup restated a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and dropped their price target for the stock from $11.00 to $5.00 in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th. Wedbush set a $5.50 price objective on Generation Bio and gave the company an “outperform” rating in a report on Tuesday, December 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Generation Bio in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Generation Bio presently has an average rating of “Hold” and a consensus target price of $8.88.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.